ePrints

Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia

Lookup NU author(s): Professor Christine Harrison FRCPath FMedSci

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2017 ISEH - International Society for Experimental Hematology. Acute myeloid leukemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure. AML is a clinically, morphologically, and genetically heterogeneous disease, and biological differences between adult and childhood AML have been identified. AML comprises 15%-20% of all children <15 years of age diagnosed with acute leukemia. Relapse occurs in up to 40% of children with AML and is the most common cause of death. Relapse arises from leukemic stem cells (LSCs) that persist after conventional chemotherapy. The treatment of AML is challenging, and new strategies to target LSCs are required. The cell surface marker CD33 has been identified as a therapeutic target, and novel anti-CD33 immunotherapies are promising new agents in the treatment of AML. This review summarizes recent developments emphasizing the genetic differences in adult and childhood AML and highlights the rationale for CD33 as a target for therapy in all age groups.

Publication metadata

Author(s): Laing AA, Harrison CJ, Gibson BES, Keeshan K

Publication type: Article

Publication status: Published

Journal: Experimental Hematology

Year: 2017

Volume: 54

Pages: 40-50

Print publication date: 01/10/2017

Online publication date: 28/06/2017

Acceptance date: 23/06/2017

ISSN (print): 0301-472X

ISSN (electronic): 1873-2399

Publisher: Elsevier Inc.

URL: https://doi.org/10.1016/j.exphem.2017.06.007

DOI: 10.1016/j.exphem.2017.06.007

Altmetrics

Share